FEDORA Study “Take-Homes” for clinicians

Clinician-led disseminator of medical news, TopMedTalk has reviewed the landmark FEDORA study into Goal-Directed Haemodynamic Therapy (GDHT).

Reinforcing the conclusions from meta-analysis of 70 other studies, FEDORA supports the use of Oesophageal Doppler to derive clinical parameters that will guide the use and timing of fluid, inotropes and vasopressors.

So how should ODM’s accurate, real-time haemodynamic data be used by the clinician?

Taken from the TopMedTalk review, which can be found here, we look at what GDHT looks like in the real world clinical setting. Prof Monty Mythen summarises it neatly: “Is there a problem? What do you think is causing the problem? Measure Haemodynamic variables, then use your brain. Is there a deficit in any area? Does the patient need volume, vasoconstrictor, vasodilator or heart contractility?”

The GDHT management algorithm is based on monitoring of “trimodal” parameters, Stroke Volume(SV), Cardiac Interval(CI) and Mean Arterial Pressure(MAP) with calls to action as follows:

  • If SV is correct, MAP is >65 and CI is >2.5, then you only need to monitor the patient.
  • If MAP is inadequate, but CI is OK, give a vasopressor (22% of patients in the FEDORA study have this protocol).
  • If CI is inadequate, give inotrope (1% of patients in the FEDORA study have this protocol)
Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Share on twitter
    Share on linkedin
    Deltex Medical Group Plc

    More articles like this

    Deltex Medical Group Plc

    Deltex Medical Group plc in a strong financial position

    Nigel Keen, Chairman of Deltex Medical, commented: “The successful £2,050,000 fund raising in February 2018 has put the Group in a stronger financial position – allowing us to improve our business structure. “We made a number of changes

    Deltex Medical Group Plc

    INTERVIEW: Deltex Medical Group New CEO Andy Mears

    Deltex Medical Group Plc (LON:DEMG) New CEO Andy Mears talks to DirectorsTalk about his new position. Andy talks about his background, how he thinks Deltex is positioned, his plans for the next 12 months and the challenges and

    Deltex Medical Group Plc

    Deltex Medical Group plc New Chief Executive

    Deltex Medical Group plc (LON:DEMG), the global leader in Oesophageal Doppler Monitoring, announced today that Ewan Phillips has resigned as Chief Executive and as a Director of the Company with immediate effect. Mr. Phillips recently approached Deltex’s Chairman indicating